Email this article 
The Effects of 5‑Aza‑2′‑Deoxycytidine and Valproic Acid on Apoptosis Induction and Cell Growth Inhibition in Colon Cancer HT 29 Cell Line
Abstract
Background: Epigenetic changes, including DNA methylation and histone modification, alter gene expression without the nucleotide template alterations and are associated with all stages of tumor formation and progression. Previously, we investigated the effects of DNA demethylating agents and histone deacetylase inhibitors on hepatocellular carcinoma and colon cancers. The current study aimed to investigate the effects of 5‑aza‑2′‑deoxycytidine (5‑AZA‑CdR, decitabine) and valproic acid (VPA), individually as well as combined on apoptosis induction and cell growth inhibition in colon cancer HT 29 cell line.
Methods: The effect of the compounds on the cell viability was measured by MTT assay. To determine cell apoptosis, the cells were treated with 5‑aza‑CdR and VPA. Propidium iodide was used for staining and the cells were analyzed using flow cytometry.
Results: Both agents decreased cell viability in a time and dose‑dependent manner significantly (P < 0.002). The results of flow cytometry demonstrated that 5‑aza‑CdR and VPA induced apoptosis significantly as opposed to control groups. Maximal percentage of apoptotic cells was obtained after 48 h with combined treatment.
Coclusions: Our findings suggest that 5‑aza‑CdR and VPA can significantly inhibit cell growth and induce apoptosis in colon cancer HT 29 cell line.
Keywords
Full Text:
PDFReferences
Ng J, Yu J. Promoter hypermethylation of tumour suppressor
genes as potential biomarkers in colorectal cancer. Int J Mol Sci
;16:2472‑96.
Grønbæk K, Treppendahl M, Asmar F, Guldberg P. Epigenetic
changes in cancer as potential targets for prophylaxis
and maintenance therapy. Basic Clin Pharmacol Toxicol
;103:389‑96.
Heichman KA, Warren JD. DNA methylation biomarkers and
their utility for solid cancer diagnostics. Clin Chem Lab Med
;50:1707‑21.
Delpu Y, Cordelier P, Cho W, Torrisani J. DNA methylation and
cancer diagnosis. Int J Mol Sci 2013;14:15029‑58.
Ropero S, Esteller M. The role of histone deacetylases (HDACs)
in human cancer. Mol Oncol 2007;1:19‑25.
Gnyszka A, Jastrzebski Z, Flis S. DNA methyltransferase
inhibitors and their emerging role in epigenetic therapy of cancer.
Anticancer Res 2013;33:2989‑96.
Singh V, Sharma P, Capalash N. DNA methyltransferase‑1
inhibitors as epigenetic therapy for cancer. Curr Cancer Drug
Targets 2013;13:379‑99.
Robertson KD, A. Jones P. DNA methylation: Past, present and
future directions. Carcinogenesis 2000;21:461‑7.
Momparler RL. Epigenetic therapy of cancer with
‑aza‑2′‑deoxycytidine (decitabine). Seminars in Oncology. 32.
Elsevier; 2005. p. 443‑51.
Federico M, Bagella L. Histone deacetylase inhibitors in the
treatment of hematological malignancies and solid tumors.
Biomed Res Int 2010;2011:1-12.
Xu W, Parmigiani R, Marks P. Histone deacetylase inhibitors:
Molecular mechanisms of action. Oncogene 2007;26:5541.
Chavez‑Blanco A, Perez‑Plasencia C, Perez‑Cardenas E,
Carrasco‑Legleu C, Rangel‑Lopez E, Segura‑Pacheco B,
et al. Antineoplastic effects of the DNA methylation inhibitor
hydralazine and the histone deacetylase inhibitor valproic acid in
cancer cell lines. Cancer Cell Int 2006;6:2.
Kavoosi F, Sanaei M. Comparative analysis of the effects of
valproic acid and tamoxifen on proliferation, and apoptosis of
human hepatocellular carcinoma WCH 17 CellLin. Iran J Ped
Hematol Oncol 2018;8:12‑20.
Sanaei M, Kavoosi F, Mansoori O. Effect of valproic acid
in comparison with vorinostat on cell growth inhibition and
apoptosis induction in the human colon cancer SW48 cells
in vitro. Exp Oncol 2018;40:95‑100.
Sanaei M, Kavoosi F, Roustazadeh A, Shahsavani H.
In vitro effect of the histone deacetylase inhibitor valproic
acid on viability and apoptosis of the PLC/PRF5 human
hepatocellular carcinoma cell line. Asian Pac J Cancer Prev
;19:2507‑10.
Sanaei M, Kavoosi F, Salehi H. Genistein and trichostatin A
induction of estrogen receptor alpha gene expression, apoptosis
and cell growth inhibition in hepatocellular carcinoma HepG
cells. Asian Pac J Cancer Prev 2017;18:3445.
Sanaei M, Kavoosi F, Atashpour S, Haghighat S. Effects of
genistein and synergistic action in combination with tamoxifen
on the HepG2 human hepatocellular carcinoma cell line. Asian
Pac J Cancer Prev 2017;18:2381.
Sanaei M, Kavoosi F, Pourahmadi M, Moosavi SN. Effect of
genistein and 17‑β estradiol on the viability and apoptosis of
human hepatocellular carcinoma HepG2 cell line. Adv Biomed
Res 2017;6:163.
Sanaei M, Kavoosi F, Roustazadeh A, Golestan F. Effect of
Genistein in comparison with trichostatin A on reactivation of
DNMTs genes in hepatocellular carcinoma. J Clin Transl Hepatol
;6:1‑6.
Sanaei M, Kavoosi F, Valiani A, Ghobadifar MA. Effect of
genistein on apoptosis and proliferation of hepatocellular
Carcinoma Hepa1‑6 Cell Line. Int J Prev Med 2018;9:12.
Okugawa Y, Grady WM, Goel A. Epigenetic alterations in
colorectal cancer: Emerging biomarkers. Gastroenterology
;149:1204‑25. e12.
Agrawal K, Das V, Vyas P, Hajdúch M. Nucleosidic DNA
demethylating epigenetic drugs–A comprehensive review from
discovery to clinic. Pharmacol Ther 2018;188:45‑79.
Chen HP, Zhao YT, Zhao TC. Histone deacetylases and
mechanisms of regulation of gene expression. Crit Rev Oncog
;20:35‑47.
Schneider‑Stock R, Diab‑Assef M, Rohrbeck A,
Foltzer‑Jourdainne C, Boltze C, Hartig R, et al. RETRACTION:
‑aza‑cytidine is a potent inhibitor of DNA methyltransferase
a and induces apoptosis in HCT‑116 colon cancer cells via
Gadd45‑and p53‑dependent mechanisms. J Pharmacol Exp Ther
;312:525‑36.
Li X, Qin B, Liu B. Delineating the effect of demethylating agent
‑aza‑2′‑deoxycytidine on human Caco‑2 colonic carcinoma
cells. Oncol Lett 2016;12:139‑43.
Rawłuszko‑Wieczorek AA, Horbacka K, Krokowicz P,
Misztal M, Jagodziński PP. Prognostic potential of DNA
methylation and transcript levels of HIF1A and EPAS1 in
colorectal cancer. Mol Cancer Res 2014;12:1112‑27.
Papi A, Ferreri A, Guerra F, Orlandi M. Anti‑invasive effects and
proapoptotic activity induction by the rexinoid IIF and valproic
acid in combination on colon cancer cell lines. Anticancer Res
;32:2855‑62.
Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F,
Formelli F, et al. Valproic acid enhances bosutinib cytotoxicity in
colon cancer cells. Int J Cancer 2009;124:1990‑6.
Yang H, Hoshino K, Sanchez‑Gonzalez B, Kantarjian H,
Garcia‑Manero G. Antileukemia activity of the combination of
‑aza‑CdR with valproic acid. Leukemia Res 2005;29:739‑48.
Gore SD, Baylin S, Sugar E, Carraway H, Miller CB,
Carducci M, et al. Combined DNA methyltransferase and histone
deacetylase inhibition in the treatment of myeloid neoplasms.
Cancer Res 2006;66:6361‑9.
Wischnewski F, Pantel K, Schwarzenbach H. Promoter
demethylation and histone acetylation mediate gene expression
of MAGE‑A1,‑A2,‑A3, and‑A12 in human cancer cells. Mol
Cancer Res 2006;4:339‑49.